CK1a1 (E42C)
Sign in to save this workspaceCSNK1A1 · Variant type: point · HGVS: p.E42C
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Sunitinib | 66.3% | 33.7% | 91.73 |
| 2 | Acalabrutinib | 27.4% | 72.6% | 99.50 |
| 3 | Erlotinib | 19.0% | 81.0% | 99.75 |
| 4 | Defactinib | 18.1% | 81.9% | 92.68 |
| 5 | Selpercatinib | 17.8% | 82.2% | 96.72 |
| 6 | Neratinib | 16.6% | 83.4% | 93.18 |
| 7 | Avapritinib | 14.4% | 85.6% | 97.73 |
| 8 | Darovasertib | 14.0% | 86.0% | 96.99 |
| 9 | Mitapivat | 12.4% | 87.6% | 100.00 |
| 10 | Umbralisib | 10.6% | 89.4% | 98.74 |
| 11 | Rabusertib | 9.5% | 90.5% | 98.74 |
| 12 | Lazertinib | 8.0% | 92.0% | 97.47 |
| 13 | Abrocitinib | 7.9% | 92.1% | 99.50 |
| 14 | Zanubrutinib | 7.8% | 92.2% | 98.24 |
| 15 | Alpelisib | 7.6% | 92.4% | 97.22 |
| 16 | Capmatinib | 7.0% | 93.0% | 99.75 |
| 17 | Entrectinib | 6.7% | 93.3% | 93.69 |
| 18 | Abemaciclib | 6.0% | 94.0% | 91.48 |
| 19 | Paxalisib | 5.1% | 94.9% | 99.75 |
| 20 | Gedatolisib | 5.1% | 94.9% | 99.75 |
| 21 | Canertinib | 4.7% | 95.3% | 96.49 |
| 22 | Tucatinib | 4.5% | 95.5% | 99.75 |
| 23 | Mobocertinib | 3.9% | 96.1% | 97.22 |
| 24 | Pralsetinib | 3.9% | 96.1% | 93.43 |
| 25 | Pexidartinib | 3.4% | 96.6% | 99.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Sunitinib | 66.3% | — | — |
| Acalabrutinib | 27.4% | — | — |
| Erlotinib | 19.0% | — | — |
| Defactinib | 18.1% | — | — |
| Selpercatinib | 17.8% | — | — |
| Neratinib | 16.6% | — | — |
| Avapritinib | 14.4% | — | — |
| Darovasertib | 14.0% | — | — |
| Mitapivat | 12.4% | — | — |
| Umbralisib | 10.6% | — | — |
| Rabusertib | 9.5% | — | — |
| Lazertinib | 8.0% | — | — |
| Abrocitinib | 7.9% | — | — |
| Zanubrutinib | 7.8% | — | — |
| Alpelisib | 7.6% | — | — |
| Capmatinib | 7.0% | — | — |
| Entrectinib | 6.7% | — | — |
| Abemaciclib | 6.0% | — | — |
| Paxalisib | 5.1% | — | — |
| Gedatolisib | 5.1% | — | — |
| Canertinib | 4.7% | — | — |
| Tucatinib | 4.5% | — | — |
| Mobocertinib | 3.9% | — | — |
| Pralsetinib | 3.9% | — | — |
| Pexidartinib | 3.4% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 32.5ms